Docoh
Loading...

114 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
. They are not guarantees of future performance. By their nature, forward-looking statements are subject to risks and uncertainties. Our actual results
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows … . Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return if the reversible inhibitor is not present
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
in the markets in which we are active, as well as our business plans. They are not guarantees of future performance. By their nature, forward-looking
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
in the U.S., or one (1) other Major Market, Ocuphire shall provide written notice to Processa specifying the nature of such reasonable belief … of such Agreement may be described in such Party’s filings with the Securities and Exchange Commission. 8.5 Equitable Relief. Given the nature
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position … the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return if the reversible inhibitor is not present, decreasing
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
advisory votes on executive compensation of the nature reflected in Proposal No. 2 above should occur every year, every two years, or every three years … , or a repurchase of Shares, that the Board determines by resolution is special or extraordinary in nature or that is in connection with a transaction
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
of future performance. By their nature, forward-looking statements are subject to risks and uncertainties. Our actual results and financial condition may
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
factors in the markets in which we are active, as well as our business plans. They are not guarantees of future performance. By their nature, forward
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and safety profiles of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return, decreasing the amount of 5
D
PCSA Processa Pharmaceuticals Inc
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes … or setoff had not occurred. 5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
8-K
EX-10.2
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
of the Agreement and shall not be deemed to limit or affect any of the provisions hereof. (l) Independent Nature of Holders’ Obligations and Rights
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return, decreasing the amount of 5-FU in the cancer cells … statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
becomes aware of the occurrence of any such event (specifying in detail the nature and scope of the event), (b) such event or occurrence shall not have
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
by DPD in order to improve the efficacy and safety profiles of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F … breakdown by DPD in order to improve the efficacy and safety profiles of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
the efficacy and safety profiles of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return, decreasing … nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return, decreasing the amount of 5-FU in the cancer cells and decreasing
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return, decreasing the amount of 5-FU … or capecitabine are administered to inhibit 5-FU breakdown by DPD in order to improve the efficacy and safety profiles of 5-FU. Given the reversible nature
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of the nature of the business conducted or to be conducted by the Company. The Company is in compliance in all material respects with the applicable … other contract or agreement relating to the relationship of such employee with HUWX or any other party because of the nature of the business conducted
S-1/A
EX-3.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, City of Dover, County of Kent, Delaware 19904. The name of its registered agent at such address is National Registered Agents, Inc. THIRD: The nature
S-1/A
EX-10.4
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
aware of the occurrence of any such event (specifying in detail the nature and scope of the event), (b) such event or occurrence shall not have been